Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy.

Scientific reports - 1 Jan 2011

Hayashi Takuma, Horiuchi Akiko, Sano Kenji, Hiraoka Nobuyoshi, Kasai Mari, Ichimura Tomoyuki, Sudo Tamotsu, Tagawa Yoh-Ichi, Nishimura Ryuichiro, Ishiko Osamu, Kanai Yae, Yaegashi Nobuo, Aburatani Hiroyuki, Shiozawa Tanri, Konishi Ikuo

Abstract excerpt

Although the majority of smooth muscle neoplasms found in the uterus are benign, uterine leiomyosarcoma (LMS) is extremely malignant, with high rates of recurrence and metastasis. We earlier reported that mice with a homozygous deficiency for LMP2, an interferon (IFN)-γ-inducible factor, spontane...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cysteine Endopeptidases
Share to Genes, Tumor Suppressor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-gamma

Share to Leiomyosarcoma

Share to Myometrium

Share to Transcriptional Activation

Share to Uterine Neoplasms

Share to Uterus

Source

Open in PubMed Open full text

Identifiers

PMID: 22355695
DOI: 10.1038/srep00180
PMCID: PMC3240965

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22355695-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy.PMID 22355695Read ↗

Efficacy of Antitumor Drugs Against Uterine Leiomyosarcoma Obtained Through the Analysis of LMP2-Deficient Mice and the Result from a Cancer Gene Panel at Cancer Genomic MedicineSemantic proximity Read ↗

Potential role of LMP2 as an anti‐oncogenic factor in human uterine leiomyosarcoma: Morphological significance of calponin h1Semantic proximity Read ↗

Molecular Pathology and Novel Clinical Therapy for Uterine Leiomyosarcoma.Semantic proximity Read ↗

Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic SubtypesSemantic proximity Read ↗

Integrative transcriptomics analysis for uterine leiomyosarcoma identifies aberrant activation of cell cycle-dependent kinases and their potential therapeutic significanceSemantic proximity Read ↗

Expression of the mitogen-inducible gene-2 (mig-2) is elevated in human uterine leiomyomas but not in leiomyosarcomasSemantic proximity Read ↗

Targeting MCM2 activates cancer-associated fibroblasts-like phenotype and affects chemo-resistance of liposarcoma cells against doxorubicin.Semantic proximity Read ↗

Differential gene expression in leiomyosarcomaSemantic proximity Read ↗

G protein pathway suppressor 2 (GPS2) acts as a tumor suppressor in liposarcomaSemantic proximity Read ↗

Subtype-Specific Tumor-Associated Fibroblasts Contribute to the Pathogenesis of Uterine Leiomyoma.Semantic proximity Read ↗

SATB2 and NGR1: potential upstream regulatory factors in uterine leiomyomas.Semantic proximity Read ↗

Increased cytoplasmic level of migfilin is associated with higher grades of human leiomyosarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.